Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies
Go back to Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies| RELYPSA (NASDAQ: RLYP) | Delayed: 31.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.99 | 52 Week High | $32.12 | |||
| Open | $3.07 | 52 Week Low | $10.26 | |||
| Day High | $31.99 | P/E | N/A | |||
| Day Low | $31.99 | EPS | $-4.54 | |||
| Volume | 79,870 | |||||
